Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults

Safety and Pharmacokinetics of Oleylphosphocholine (OlPC), Administered Orally in Healthy Adults: A Phase 1, Single Center, Open-label, Staggered, Dose-escalation Trial

The goal of this interventional study is to assess the safety and tolerability of OlPC and to characterize the pharmacokinetics (PK) of OlPC following single, ascending doses administered orally in healthy-fed subjects.

Study Overview

• Status: Terminated
• Conditions: Leishmaniasis
• Intervention / Treatment: Drug: Oleylphosphocholine

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Meral MD Esen, Medical doctor; Phone Number: +49 70712982365; Email: itmpm@med.uni-tuebingen.de

Study Locations

• Germany
  • Tübingen, Germany, 72074
    • Institute for Tropical Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy males and females of non-childbearing (see below) potential.

   1. 18 - 60 years of age.
   2. BMI between 20-30 and body weight from 55-100 kg.

2. Females of non-childbearing potential defined as follows:

   1. Surgically sterile (history of bilateral tubal ligation/occlusion, bilateral oophorectomy or hysterectomy) or
   2. Postmenopausal, defined as amenorrhea for ≥ 12 consecutive months prior to screening without an alternative medical cause. A follicle-stimulating hormone (FSH) level will be measured to confirm postmenopausal status.

3. Males must agree:

   1. to use a latex condom during any sexual contact with while participating in the study and for 3 months following discontinuation from this study, even if he has undergone a successful vasectomy.
   2. to refrain from donating semen or sperm during study participation and for 3 months after discontinuation from this study.
4. Able and willing (in the investigator's opinion) to comply with all trial requirements.
5. Available to participate in follow-up for the duration of trial.
6. Living in the area close enough to be able to attend all follow-up visits.
7. General good health based on the definition in BreithauptGrögler et al. 2017 and based on history, clinical examination and laboratory results.
8. Signed informed consent.
9. Consent to provide clinical history and if necessary consent that the study team is allowed to contact the family doctor of the participant.
10. All subjects are forbidden from donating blood while on study drug and for 3 months after discontinuation from this study

Exclusion Criteria:

1. Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia, recurrent, severe infections and chronic immunosuppressant medication (more than 14 days) within the past 6 months.
2. Any history of or signs of hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic clinical significant abnormalities.
3. History of chronic infections (e.g., hepatitis В or С) and chronic inflammation.
4. History of significant, acute or chronic gastrointestinal, hepatic, cardiac or renal disorders.
5. History of leishmaniasis.
6. History of hypersensitivity to the excipients present in the investigational medicinal product or to any drug with similar chemical structure (Miltefosine).
7. Use of immunoglobulins or blood products within 3 months prior to enrolment.
8. Receipt of any investigational medicinal product in the 30 days preceding enrolment, or planned receipt during the trial period.
9. Participation in other clinical trials or observation period of competing trials.
10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ in the last five years).
11. Mental disorders or other psychiatric conditions (including depression).
12. The average alcohol intake greater than 24 g pure alcohol per day for men or greater than 12 g pure alcohol per day for women (including history of possible addiction) and alcohol consumption on more than five days a week.
13. Suspected or known injecting drug abuse in the 5 years preceding enrolment.
14. Participants unable to be closely followed for social, geographic or psychological reasons.
15. Any clinically significant abnormal finding on biochemistry or hematology blood tests, urine analysis or clinical examination.
16. History of seizure, except for sporadic childhood febrile convulsions.
17. Sjoegren-Larsson-Syndrome (SLS).
18. Participants who are unwilling to ingest the food provided.
19. Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Oleylphosphocholine capsules (IMP) oral administration; Participants will receive once Oleylphosphocholine (capsule/s) orally as a single dose under fed conditions.

Drug: Oleylphosphocholine; The trial is a dose escalation trial that follows a 3+3 approach. The sample size is determined by a decision-making algorithm and by the tolerability of the study drug in the study participants. This design follows predetermined rules that help identify notable toxicities in time with a reasonable degree of accuracy. The initial dose will be 50mg OlPC (1 capsule) and participants in subsequent cohorts will receive 100mg (2 capsules), 150mg (3 capsules), 200mg (4 capsules), 250mg (5 capsules), or 300mg (6 capsules) if the previous doses are tolerated. The study ends when the last cohort is completed or when it is determined that a dose (within a cohort) is not tolerable.; Other Names: OlPC

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Subject incidence of treatment-emergent adverse events at administration and follow-up visits	Participants are followed up for 21 days and an additional telephone visit 35 days after drug administration will be conducted before dismissing the participant.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Maximum observed concentration in plasma after single dose (µg/mL)	21 days
Tmax	Time of maximum observed concentration (h)	21 days
AUC0-t	Area under the curve (AUC) from time 0 to the time of the last measurable concentration, calculated using the Linear Up / Log Down trapezoidal rule (h*µg/mL)	21 days
AUC0-24	Area under the curve from time 0 to hour 24 (single-dose only), calculated using the Linear Up / Log Down trapezoidal rule (h*µg/mL)	21 days
AUC0-inf	Area under the curve from time 0 to infinity (single-dose only), calculated as AUC0-inf = AUC0-t + Ct / λz, where Ct is the last observed quantifiable concentration and λz is the elimination rate constant (h*µg/mL)	21 days
t1/2	Elimination half-life, calculated as ln(2) / λz (h)	21 days
AUCres	Residual Area: extrapolated area (single-dose) calculated as AUCres = 100 (AUC(0-inf) - AUC(0-t)) / AUC(0-inf)	21 days

Collaborators and Investigators

• Sponsor: University Hospital Tuebingen

Publications and helpful links

Helpful Links

• Official website

Study record dates

Study Major Dates

• Study Start (Actual): June 21, 2023
• Primary Completion (Actual): February 27, 2024
• Study Completion (Actual): February 27, 2024

Study Registration Dates

• First Submitted: August 31, 2023
• First Submitted That Met QC Criteria: November 8, 2023
• First Posted (Actual): November 9, 2023

Study Record Updates

• Last Update Posted (Actual): March 12, 2024
• Last Update Submitted That Met QC Criteria: March 7, 2024
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Infections; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Skin Diseases, Parasitic; Skin Diseases, Infectious; Euglenozoa Infections; Leishmaniasis
• Other Study ID Numbers: TT4CL_EKUT; 2021-004936-27 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No